NAUT
Nautilus Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.33
−1.06%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +2.3%
- EBIT
- +10.3%
- EPS
- +8.0%
- Free cash flow
- -2.3%
- Operating cash flow
- +0.3%
Forward estimates
Based on analyst estimates
- Revenue
- +590.8%
- EBITDA
- -10.6%
- EPS
- -10.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- +18.5%
- EBIT
- +18.0%
- Net income
- +16.6%
- EPS
- +16.1%
- Free cash flow
- +15.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026